Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$4 Mln
P/E Ratio
--
P/B Ratio
0.64
Industry P/E
--
Debt to Equity
--
ROE
-0.5 %
ROCE
-50.12 %
Div. Yield
0 %
Book Value
3.9
EPS
-2.57
CFO
$-55.55 Mln
EBITDA
$-99.44 Mln
Net Profit
$-134.83 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Xenetic Biosciences (XBIO)
| -39.06 | -30.53 | -42.83 | -39.44 | -39.72 | -22.14 | -43.93 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Xenetic Biosciences (XBIO)
| 15.52 | 21.01 | -77.91 | -36.76 | 41.67 | -92.68 | -14.44 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by... targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies. The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts. Address: 945 Concord Street, Framingham, MA, United States, 01701 Read more
CEO, President & Director
Mr. Jeffrey F. Eisenberg Esq.
CEO, President & Director
Mr. Jeffrey F. Eisenberg Esq.
Headquarters
Framingham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Xenetic Biosciences Inc (XBIO) stood at $ 7 Mln as on 31-Dec-24
The share price of Xenetic Biosciences Inc (XBIO) is $2.43 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Xenetic Biosciences Inc (XBIO) has given a return of -39.72% in the last 3 years.
Xenetic Biosciences Inc (XBIO) has a market capitalisation of $ 4 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Xenetic Biosciences Inc (XBIO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Xenetic Biosciences Inc (XBIO) and enter the required number of quantities and click on buy to purchase the shares of Xenetic Biosciences Inc (XBIO).
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies. The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts. Address: 945 Concord Street, Framingham, MA, United States, 01701
The CEO & director of Mr. Jeffrey F. Eisenberg Esq.. is Xenetic Biosciences Inc (XBIO), and CFO & Sr. VP is Mr. Jeffrey F. Eisenberg Esq..
There is no promoter pledging in Xenetic Biosciences Inc (XBIO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Xenetic Biosciences Inc. (XBIO) | Ratios |
|---|---|
|
Return on equity(%)
|
-50.12
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-158.39
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Xenetic Biosciences Inc (XBIO) was $0 Mln.
$0.02
(
